Association between apolipoprotein A-IV concentrations and chronic kidney disease in two large population-based cohorts: Results from the KORA studies

Journal of Internal Medicine

Volumn 278, Issue 4, 2015, Pages 410-423

  Stangl, S ^a   Kollerits, B ^a   Lamina, C ^a   Meisinger, C ^b   Huth, C ^b,c   Stockl A ^a   Dahnhardt D ^a   Boger C A ^d   Kramer B K ^e   Peters, A ^b   Kronenberg, F ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^d UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^e MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

Author keywords

Albuminuria; Apolipoprotein A IV; Chronic kidney disease; Glomerular filtration rate; Kidney function impairment

Indexed keywords

ALBUMIN; APOLIPOPROTEIN A4; CREATININE; APOLIPOPROTEIN A; APOLIPOPROTEIN A-IV;

ADULT; AGE DISTRIBUTION; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MIDDLE AGED; POPULATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; BLOOD; CHRONIC KIDNEY FAILURE; STATISTICAL MODEL;

APOLIPOPROTEINS A; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC;

EID: 84941025931     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12380     Document Type: Article

References (37)

1. Levey AS, de Jong PE, Coresh J et al. The definition, classification, and prognosis of chronic kidney disease: A KDIGO Controversies Conference report. Kidney Int 2011; 80: 17-28.
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-305.
3. de Jager DJ, Grootendorst DC, Jager KJ et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 2009; 302: 1782-9.
4. Utermann G, Beisiegel U. Apolipoprotein A-IV: a protein occurring in human mesenteric lymph chylomicrons and free in plasma. Isolation and quantification. Eur J Biochem 1979; 99: 333-43.
5. Green PH, Glickman RM, Riley JW, Quinet E. Human apolipoprotein A-IV. Intestinal origin and distribution in plasma. J Clin Invest 1980; 65: 911-9.
6. Ezeh B, Haiman M, Alber HF et al. Plasma distribution of apoA-IV in patients with coronary artery disease and healthy controls. J Lipid Res 2003; 44: 1523-9.
7. Steinmetz A, Barbaras R, Ghalim N et al. Human apolipoprotein A-IV binds to apolipoprotein A-I/A-II receptor sites and promotes cholesterol efflux from adipose cells. J Biol Chem 1990; 265: 7859-63.
8. Stein O, Stein Y, Lefevre M, Roheim PS. The role of apolipoprotein A-IV in reverse cholesterol transport studied with cultured cells and liposomes derived from an ether analog of phosphatidylcholine. Biochim Biophys Acta 1986; 878: 7-13.
9. Goldberg IJ, Scheraldi CA, Yacoub LK, Saxena U, Bisgaier CL. Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV. J Biol Chem 1990; 265: 4266-72.
10. Steinmetz A, Utermann G. Activation of lecithin: cholesterol acyltransferase by human apolipoprotein A-IV. J Biol Chem 1985; 260: 2258-64.
11. Guyard-Dangremont V, Lagrost L, Gambert P. Comparative effects of purified apolipoproteins A-I, A-II, and A-IV on cholesteryl ester transfer protein activity. J Lipid Res 1994; 35: 982-92.
12. Duverger N, Tremp G, Caillaud JM et al. Protection against atherogenesis in mice mediated by human apolipoprotein A-IV. Science 1996; 273: 966-8.
13. Cohen RD, Castellani LW, Qiao JH et al. Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV. J Clin Invest 1997; 99: 1906-16.
14. Kronenberg F, Stuhlinger M, Trenkwalder E et al. Low apolipoprotein A-IV plasma concentrations in men with coronary artery disease. J Am Coll Cardiol 2000; 36: 751-7.
15. Manpuya MW, Guo J, Zhao Y. The relationship between plasma apolipoprotein A-IV levels and coronary heart disease. Chin Med J (Engl) 2001; 114: 275-9.
16. Omori M, Watanabe M, Matsumoto K et al. Impact of serum apolipoprotein A-IV as a marker of cardiovascular disease in maintenance hemodialysis patients. Ther Apher Dial 2010; 14: 341-8.
17. Lingenhel A, Lhotta K, Neyer U et al. Role of the kidney in the metabolism of apolipoprotein A-IV: influence of the type of proteinuria. J Lipid Res 2006; 47: 2071-9.
18. Kronenberg F, Kuen E, Ritz E et al. Apolipoprotein A-IV serum concentrations are elevated in patients with mild and moderate renal failure. J Am Soc Nephrol 2002; 13: 461-9.
19. Kollerits B, Krane V, Drechsler C et al. Apolipoprotein A-IV concentrations and clinical outcomes in haemodialysis patients with type 2 diabetes mellitus-a post hoc analysis of the 4D Study. J Intern Med 2012; 272: 592-600.
20. Qin X, Tso P. The role of apolipoprotein AIV on the control of food intake. Curr Drug Targets 2005; 6: 145-51.
21. Boes E, Fliser D, Ritz E et al. Apolipoprotein A-IV predicts progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2006; 17: 528-36.
22. Kronenberg F, Konig P, Neyer U et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1995; 6: 110-20.
23. Sun Z, Larson IA, Ordovas JM, Barnard JR, Schaefer EJ. Effects of age, gender, and lifestyle factors on plasma apolipoprotein A-IV concentrations. Atherosclerosis 2000; 151: 381-8.
24. Heidelberg DA, Holle R, Lacruz ME, Ladwig KH, von Lengerke T. Do diabetes and depressed mood affect associations between obesity and quality of life in postmenopause? Results of the KORA-F3 Augsburg population study. Health Qual Life Outcomes 2011; 9: 97.
25. Rathmann W, Kowall B, Tamayo T et al. Hemoglobin A1c and glucose criteria identify different subjects as having type 2 diabetes in middle-aged and older populations: the KORA S4/F4 Study. Ann Med 2012; 44: 170-7.
26. Kronenberg F, Lobentanz EM, Konig P, Utermann G, Dieplinger H. Effect of sample storage on the measurement of lipoprotein[a], apolipoproteins B and A-IV, total and high density lipoprotein cholesterol and triglycerides. J Lipid Res 1994; 35: 1318-28.
27. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-12.
28. Pencina MJ, D'Agostino RB Sr, Demler OV. Novel metrics for evaluating improvement in discrimination: net reclassification and integrated discrimination improvement for normal variables and nested models. Stat Med 2012; 31: 101-13.
29. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-72.
30. Dieplinger H, Lobentanz EM, Konig P et al. Plasma apolipoprotein A-IV metabolism in patients with chronic renal disease. Eur J Clin Invest 1992; 22: 166-74.
31. Kronenberg F, Lingenhel A, Neyer U et al. Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients. Kidney Int Suppl 2003; 84: S113-6.
32. Massy ZA, Kandoussi AM, Mamzer-Bruneel MF et al. High serum apolipoprotein AIV levels in renal transplant recipients. Clin Nephrol 2001; 55: 156-8.
33. Seishima M, Muto Y. An increased apo A-IV serum concentration of patients with chronic renal failure on hemodialysis. Clin Chim Acta 1987; 167: 303-11.
34. Haiman M, Salvenmoser W, Scheiber K et al. Immunohistochemical localization of apolipoprotein A-IV in human kidney tissue. Kidney Int 2005; 68: 1130-6.
35. Qin X, Swertfeger DK, Zheng S, Hui DY, Tso P. Apolipoprotein AIV: a potent endogenous inhibitor of lipid oxidation. Am J Physiol 1998; 274: H1836-40.
36. Kronenberg F. Emerging risk factors and markers of chronic kidney disease progression. Nat Rev Nephrol 2009; 5: 677-89.
37. Glassock RJ, Winearls C. Ageing and the glomerular filtration rate: truths and consequences. Trans Am Clin Climatol Assoc 2009; 120: 419-28.